[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649983":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":20,"responsibleParty":43,"collaborators":11,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":11,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":22,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Centre Hospitalier Intercommunal Aix-Pertuis","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"monitoring of muscle relaxation","EXPERIMENTAL",null,[13],"Device: neuromuscular blockade monitoring",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DEVICE","neuromuscular blockade monitoring","The goal of monitoring neuromuscular blockade in an intensive care patient is to ensure the effectiveness of the technique through adequate neuromuscular blockade. In addition to a clinical assessment based on observation of respiratory effort or detection of patient-ventilator asynchrony, this monitoring includes the use of quantitative methods with TOFscan Idmed device to evaluate neuromuscular blockade: \"TOF\" and \"PTC.\" The use of neuromuscular blocking agents and their monitoring are governed by a standard care protocol in each participating center. The investigators will study, within the context of routine care, the reliability and reproducibility of this technique, which was initially applied and validated in patients in the operating room and subsequently adapted for use in intensive care patients.",[9],[21],{"facility":5,"status":22,"city":23,"state":11,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Aix-en-Provence","13090","France","FR",{"type":28,"coordinates":29},"Point",[30,31],5.44973,43.5283,{"lat":31,"lon":30},[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Clinical research manager","CONTACT","04.42.33.56.50","+33","rechercheclinique@ch-aix.fr",{"name":41,"role":42,"phone":11,"phoneExt":11,"email":11},"Romain Ronflé, Dr","PRINCIPAL_INVESTIGATOR",{"type":42,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Romain Ronfle","principal investigator","100649983","monitoring-of-neuromuscular-blockade-in-the-intensive-care-unit-a-reliability-study-100649983",false,"NCT07741851","Monitoring of Neuromuscular Blockade in the Intensive Care Unit: a Reliability Study","CURAREA","Inclusion Criteria:\n\n* Adult patients\n* Patients admitted to the intensive care unit who have been receiving neuromuscular blocking agents for at least 24 hours during their stay - Consent obtained from the patient or emergency consent obtained from family members\n* Patients covered by the French social security system, regardless of the specific plan\n\nExclusion Criteria:\n\n* Patients who have already been exposed to prolonged neuromuscular blockade or who have been receiving continuous neuromuscular blockade for less than 24 hours\n* Allergy to neuromuscular blocking agents\n* Patients with a neurological condition that alters the interpretation of neuromuscular blockade or contraindicates the use of neuromuscular blocking agents\n* Patients enrolled in an interventional study\n* Patients who object to the collection of their medical data for this study\n* Patients under the age of 18\n* Patients deprived of their liberty, under guardianship, or under conservatorship\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":56,"type":57},160,"ESTIMATED","INTERVENTIONAL",[60],"NA","The objective of this clinical trial is to evaluate the reliability of neuromuscular blockade monitoring in adult intensive care patients depending on the clinical context.\n\nThe main questions it aims to answer are as follows:\n\n* Detection of an anomaly at ulnar \"TOF\" stimulation in patients without neuromuscular blockade\n* Absence of adverse events during clinical monitoring of neuromuscular blockade (every 24 hours): absence of respiratory effort movements or patient-ventilator asynchrony (safety)",[63],"Neuromuscular Blockade Monitoring",[65,66,67,68],"intensive care","neuromusculare blockade monitoring","cisatracurium","TOF","2026-07-28",{"date":71,"type":72},"2026-08-03","ACTUAL",{"date":74,"type":72},"2026-04-02",{"date":76,"type":57},"2027-01",{"name":5,"class":6},1]